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Abstract: Gemcitabine is a broad-spectrum antimetabolite and a deoxycytidine analog recognized as a standard therapy alone or in
combination with other antineoplastic agents in the therapy of pancreas cancer. Drug resistance following gemcitabine treatment is a
common phenomenon; therefore, combinational therapy models are usually preferred. Pancreatic ductal adenocarcinoma, or pancreas
cancer, is the fourth leading cause of cancer-related deaths worldwide. With the increasing incidence of pancreatic cancer every year,
the mortality rate is also rising significantly because of late diagnosis, and limited chemotherapy options. Adjuvant chemotherapy after
surgical resection is the typical option for the treatment of early pancreatic cancer. Mostly, 5-fluorouracil/leucovorin with irinotecan
and oxaliplatin (FOLFIRINOX) and gemcitabine/nab-paclitaxel is used for the prognosis of advanced pancreatic cancer; however,
chemoresistance usually occurs limiting the effectiveness of the chemotherapy. Therefore, most of the studies are focused on gemcitabine
combination with other drugs to overcome the situation.
As an apoptotic agent and a member of brassinosteroids, epibrassinolide (EBR) induces endoplasmic reticulum (ER) stress-dependent
cell death in different cancer cells, as shown by our group. In this study, we aimed to enhance the gemcitabine apoptotic effect by EBR
combined treatment in pancreatic cancer cells. EBR treatment reduced cell viability and inhibited cell proliferation in PANC-1, MIA
PaCa-2, and AsPC-1 cells. Each pancreatic cancer cell gave different responses to the EBR treatment because of different aggressiveness.
However, EBR induced apoptosis through increasing ROS generation, which was associated with ER stress in PANC-1 and MIA PaCa2 cells. Gemcitabine alone reduced the cell viability of each pancreatic cancer cell line; however, combination with EBR led to further
induction of apoptotic cell death in each pancreatic cancer cell line. In addition, combined treatment of gemcitabine and EBR further
decreased N-cadherin and vimentin expressions, suggesting that epithelial-mesenchymal transition of pancreatic cells is reduced. In
conclusion, EBR had therapeutic potential to avoid the gemcitabine-induced side effects during the treatment of pancreatic cancer.
Key words: Pancreatic cancer, endoplasmic reticulum stress, epibrassinolide, gemcitabine

1. Introduction
The pancreas, as a secretory nodular gland, is a critical
center of energy consumption and metabolism of the
gastrointestinal system. Pancreatic cancer, with poor
outcomes, keeps one of the most malignant neoplasms
as well as being the most lethal condition, particularly in
developed countries. The two major types of pancreatic
cancer are ductal adenocarcinoma (PDAC) which includes

about 85% of cases, and less than 5% of all cases are
pancreatic neuroendocrine tumors (NETs) (McGuigan et
al., 2018). Early detection is considered the most efficient
way to boost survival in pancreatic cancer. Unfortunately,
tumor formation and development are asymptomatic
in general, and the disease only becomes conspicuous
after metastasis (Melisi et al., 2018). Pancreatic cancer
has been separated into subtypes according to the
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transcription factors profiles, integrated genomic analysis,
the prevalence of aberrations in key driver genes, core
signaling pathways, and downstream targets. The
next-generation sequencing data from PDAC patients
showed mostly mutated genes playing a role in cell cycle
progression, DNA repair, RNA processing, chromatin
modification, tumor suppressors, etc. Especially K-Ras,
TGF-β, Wnt, Notch, and SWI-SNF signaling pathways
have been shown to be altered during PDAC (Pelosi et
al., 2017). Resistance mechanisms improved by tumors
and unfavorable responses to current therapies emphasize
the need to evolve alternative treatment approaches.
Gemcitabine is an anticancer nucleoside and the analog
of deoxycytidine. Once gemcitabine is transported to the
cell, it is phosphorylated by deoxycytidine kinase to an
active form. It exerts the antitumor effect by suppressing
the activity of ribonucleotide reductase, thus inhibiting
DNA synthesis and blocking cell proliferation and division
(Plunkett et al., 1995). The clinical benefit of gemcitabine
is approximately five times higher than 5-fluorouracil (5FU): although its effect on survival is limited. The poor
penetration of the drug into the hyper vascularized, dense
tumor stroma and the development of chemoresistance
restrict the use of gemcitabine and it is usually preferred
in combinational therapy models (Oettle & Riess, 2002).
It has been shown that Akt, epithelial growth factor
receptor (EGFR): MAPK signaling pathways involved in
the formation of gemcitabine resistance, and cells in the
epithelial-mesenchymal transition (EMT) phenotype
play an active role in pancreatic cancer chemoresistance.
EMT is a cellular process during which cells change their
morphology to lose epithelial, and gain mesenchymal
properties and metastatic profile via enhanced migratory
capacity, invasiveness, and elevated resistance to apoptosis.
EMT is characterized by the downregulation of E-cadherin,
a parallel increase in the expressions of N-cadherin and
vimentin (Sommariva & Gagliano, 2020). These protein
expression alterations are provided by transcription
factors Slug, Snail, Zeb1/2, and SMAD-interacting protein
1. Different mechanisms like cytokine signaling, growth
factors, and endoplasmic reticulum stress can lead to EMT
in different carcinomas, including PDAC (De Wever et al.,
2008).
In eukaryotic cells, the biosynthesis, folding, and
modifications of secretory and membrane proteins are
conducted by the endoplasmic reticulum (ER) (Benham,
2019). Cellular redox regulation disturbance, glucose
deprivation, viral infections, and chemotherapeutics can
cause an accumulation of un-/misfolded proteins in the ER,
triggering an evolutionarily conserved response termed
the unfolded protein response (UPR). To maintain cell
homeostasis under stress conditions, UPR induces certain
signaling pathways to support protein folding, decrease
translation activity to limit unprocessed protein amounts,
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and degrade un-/misfolded protein through the ubiquitinproteasome pathway. These decisions are made following
the chaperone protein GRP78/BiP dissociation from three
transmembrane sensor proteins in the ER, namely PERK,
IRE1α, and ATF6 (Wang & Kaufman, 2012). The PERKmediated response includes ATF4 activation following
eIF2α phosphorylation, resulting in CHOP translocation
to the nucleus. CHOP is a critical player in the decision
of apoptotic cell death by repressing the antiapoptotic
protein Bcl-2 and activation of proapoptotic BH3
domain-only proteins such as Bax. The IRE1-mediated
ER stress response initiates with oligomerization and
autophosphorylation following Grp78/BiP dissociation.
Once IRE1α is autophosphorylated, its endoribonuclease
activity is induced and splices XBP-1 mRNA to produce an
active XBP-1 protein. The mature protein is a transcription
factor for genes involved in protein homeostasis. IRE1α
signaling can also stimulate Jun-N-Terminal kinase (JNK)
and p38 via induction of apoptotic signaling kinase 1
(ASK1). JNK and p38 have been shown to promote the
phosphorylation and activation of proapoptotic Bax. The
third ER stress-induced signaling cascade begins with
ATF6 release from Grp78/BiP and translocation to the
Golgi followed by proteolytic cleavage of the N-terminal
fragment processed by Site-1 (S1P) and Site-2 (S2P)
proteases. Upon maturation, ATF6 is transported into the
nucleus to turn on gene expression such as CHOP, GRP78,
and XBP1. ATF6 signaling also triggers JNK, Rheb/mTOR,
and apoptosis pathways. Besides, it has been demonstrated
that caspase-12, which is directly activated by ER stress, is
translocated from the ER to the cytoplasm and causes the
activation of caspase-9, known as the cell death initiating
caspase (Lin et al., 2019).
Brassinosteroids (BR) are a group of steroids involved
in plant growth, development, and stress responses (Nolan
et al., 2020). It is noteworthy that BRs have also remarkable
biological activity such as antiangiogenic, anticancer,
antigenotoxic, antiviral, antifungal, and antibacterial
in animal systems shown in both in vitro and in vivo
studies (Kohli et al., 2020). Our recent studies showed
that epibrassinolide (EBR): a member of BRs exerts an
apoptotic effect in cancer cells by modulating several
signaling pathways and metabolisms including PI3K/Akt
and polyamines. Our recent studies enlighten the main
target of EBR as calreticulin (CALR): an endoplasmic
reticulum resident protein playing a role in protein
folding. The SILAC (stable isotope labeling with amino
acids in cell culture) assay and verification experiments
via overexpression and silencing CALR have indicated
that UPR and ER stress play a crucial role in EBR-induced
apoptosis [13][14]. Besides, due to the natural origin of
EBR, it does not induce toxic effects in mouse embryonic
fibroblasts (MEF) or human fetal colon epithelial cells at
micromolar concentrations, unlike cancer cells. Our aim
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in this study is to check the ability of EBR to enhance
gemcitabine sensitivity in pancreatic cells by investigating
apoptotic signaling pathways as well as the expressions of
drug resistance influencing ER stress and EMT process
proteins.
2. Materials and methods
2.1. Materials
EBR was purchased from Apollo Scientific (Manchester,
UK) and dissolved in DMSO (stock concentration 5 mM).
Gemcitabine was purchased from Sigma Aldrich (St. Louis,
MO, USA) and prepared at a 150 mM stock concentration.
Caspase 9, Caspase 7, Bcl-2, Bax, Puma, Bim, Bak, Bid, BiP,
CALR, CALNX, PDI, IRE1a, PERK, Ero1La antirabbit or
antimouse antibodies were purchased from Cell Signaling
Technology (each 1:1000, CST, Danvers, MA, USA).
Loading control B-actin and GAPDH antibodies and
HRP-conjugated secondary antirabbit and antimouse were
purchased from CST.
2.2. Cell lines and cell culture
MIA PaCa-2, PANC-1, and AsPC1 cells were purchased
from American Tissue and Cell Culture (ATCC). MIA
PaCa-2 and PANC-1 cells were grown in DMEM medium
and AsPC1 cells in RPMI medium with the addition of 10%
fetal bovine serum and 10 U/mL penicillin/streptomycin
at 37° C in a humidified 5% CO2 incubator (HERAcell
150; Thermo Electron Corporation, Waltham, MA, USA).
2.3. Cell viability assay
Cells were seeded at a 1 × 104 density of cells/well in 96well plates and exposed to EBR and (or) GEM at different
time points. Ten microliters of 3-(4,5-dimethylthiazol2-yl)-2,5- diphenyl tetrazolium bromide dye (5 mg/mL)
(Sigma-Aldrich) were added to each well and cells were
kept at 37 °C for 4 h. The resulting formazan crystals were
solubilized in 200 μL of dimethyl sulfoxide (DMSO). The
density of the solubilized formazan was read at 570 nm
spectrophotometrically (Bio-Rad, Hercules, CA, USA).
2.4. Colony formation assay
Cells were seeded at a 1 × 104 density of cells/well into
6-well plates and treated with EBR and/or GEM. The
media were then removed and cells were washed with
1X PBS fixed with methanol: acetic acid (3:1) for 5 min.
Following the removal of fixing agents, cells were stained
with 0.5% crystal violet in methanol for 15 min, washed
with distilled water, and the morphological images were
taken under light microscopy.
2.5. Trypan blue dye exclusion assay
Cells were seeded at a 1 × 105 density of cells/well in 6-well
plates (TPP, Zollstrasse, Switzerland) and treated with
EBR and/or GEM time-dependently within 96 h. After
trypsinization (Trypsin EDTA (0.25%): Gibco, USA): and
centrifugation, cells were exposed to 0.4% (w/v) Trypan
Blue (Gibco, USA) and cell culture media at a 1:1 ratio.

Ten microliters of cells were counted by a dual-chamber
0.1 mm deep Neubauer improved hemocytometer.
2.6. Wound healing assay
Cells were seeded at a 1×106 density of cells/well and
grown to 80% confluence in 35 mm plates. The cell
monolayer was then scratched with the narrow end of a
sterile 200-µL pipette tip. Subsequently, the medium was
promptly replaced to eliminate floating cells. The width
of the scratch was measured at two points in each well
after initial wounding. The cells were incubated for 24 h
at 37 °C in a CO2 incubator, and then, the scratch width
was remeasured. The relative motility and migration
ability of the cells into the cell-free zone is expressed as the
normalized percent change in the scratch width after 24,
48, and 72 h.
2.7. Immunoblotting
Cells were cultured in 60-mm Petri dishes in a complete
medium. The media were then discarded and the cells were
washed with ice-cold 1X PBS and lysed with ProteoJET
Mammalian cell lysis buffer (Fermentas, St. Leon-Rot,
Germany). For cytoplasmic and nuclear protein extraction
NE-PER nuclear and cytoplasmic extraction kit (Thermo
Scientific, Rockford, IL, USA) was used according to
the manufacturer’s instructions. Total, cytoplasmic, and
nuclear protein levels were determined by the Bradford
method (Bio-Rad, Hercules, CA, USA). Total cell lysates
were separated by 12% SDS–PAGE gels and transferred
onto polyvinylidene difluoride (PVDF) membranes
(Roche) subjected to electrophoresis. Membranes were
washed in tris-buffered saline with Tween-20 (TBS-T)
(10 mM Tris-HCl (pH 8.3): 0.05% Tween-20) (Tween 20,
Sigma Ultra, St. Louis, MO, USA). Blocking was preceded
by 5% skim milk containing TBS-T milk overnight at
4 °C. PVDF membranes were incubated with a primary
antibody buffer containing 5% (v:v) skim milk solution
with appropriate antibodies. Membranes were rinsed with
TBS plus 0.05% v/v Tween-20 and incubated overnight
with horseradish peroxidase (HRP)-conjugated secondary
antibodies (antirabbit IgG, 1:5000 (v:v)) at 4 °C. Following
the addition of an enhanced chemiluminescence
reagent, signals from the HRP-coupled antibodies were
detected using ChemiDoc MP Imaging System (Bio-Rad
Laboratories, Hercules, CA). All results were replicated at
least three times and representative blots were given.
2.8. Statistical analysis		
All the experiments were statistically analyzed by GraphPad
Prism 6 software (http://www.graphpad.com/). Error bars
in the graphs were generated using ± standard deviation
(SD) values. A statistical significance test was utilized by
using ANOVA Bonferroni’s multiple comparisons test. p
< 0.05 was taken as a level of significance. The results were
repeated at least three times. The immunoblotting results
shown are representative of three separate experiments.
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3. Results
3.1. Epibrassinolide (EBR) treatment decreased cell
viability, growth, and colony formation of pancreatic
cells
To evaluate the effect of EBR on the cell viability of
pancreatic cells, MIA PaCa-2 and PANC-1 cells were
treated with EBR in a dose-dependent manner (1–30
µM) for 24 h (Figure 1A). According to MTT cell viability
assay results, while all concentrations of EBR treatment
reduced the cell viability of MIA PaCa-2 cells significantly,
a significant decrease in cell viability from 10 µM EBR
concentration was observed in PANC-1 cells for 24 h. It
was recorded that 1 and 10 µM EBR decreased cell viability
by 20% and 40% in MIA PaCa-2 cells, respectively. While
10 µM EBR led to 45% of cell viability loss, there was no
difference in 1 µM-treated PANC-1 cells. To understand
the effect of EBR on more aggressive pancreatic cancer
cells, AsPC-1 cells were cultured and treated with 10, 20,
and 30 µM EBR for 24, 48, and 72 h (Figure 1B). The cell
viability loss was recorded by 20% and 40% decrease after
24 h treatment of 10 and 20–30 µM EBR. The doubling
time of AsPC-1 was around 38 h and the proliferation
rate was higher than MIA PaCa-2 and PANC-1 cells.
Therefore, 20 and 30 µM treatment of EBR decreased the
cell viability by 30% and 40% for 48 h, while 40% and 45%
for 72 h, respectively. To confirm these data, a trypan blue
dye exclusion assay was performed. As shown in Figures
1C and 1D, the cytostatic effect of EBR treatment was
observed in each cell line. While the proliferation ability
of PANC-1 cells was strictly inhibited by EBR treatment,
the proliferation rate of MIA PaCa-2 cells was slowed
down until 48 h treatment. However, the effect of EBR
for 72 h treatment was not effective for the inhibition of
cell survival in MIA PaCa-2 cells. The long-term effect of
EBR on MIA PaCa-2 and PANC-1 cells was investigated by
colony formation assay (Figures 1E and 1F). MIA PaCa-2
and PANC-1 cells were treated with 1–10 µM EBR and it
was observed that 1 µM EBR was enough to inhibit the
colony-forming potential of the PANC-1 cells, but not
in MIA PaCa-2 cells. As shown in Figures 1E and 1F, 10
µM EBR blocked the colony-forming ability of both MIA
PaCa-2 and PANC-1 cells. Moreover, the effect of EBR on
the migration potential of cells was investigated by wound
healing assay. One and 10 µM EBR-treated and -untreated
PANC-1 and MIA PaCa-2 cells were observed for 24 and
48 h. The distance in the wound area in untreated cells
decreased significantly, whereas the closing rate of the
wounds decreased by EBR treatment in both MIA PaCa-2
(Figures 2A and 2B) and PANC-1 cells (Figures 2C and
2D).
3.2. EBR induced apoptotic cell death in PANC-1 and
MIA PaCa-2 cells
To further investigate the mechanistic effect of EBRinduced cell death, EBR-treated cells were stained with PI,
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DiOC6, DCFH-DA, and DAPI (Figure 3A). The result of
PI staining confirmed the MTT cell viability assay, in which
increasing red dots showed death cells following 10 µM
EBR treatment. EBR induced the mitochondrial membrane
potential loss that led to a decrease in DiOC6 staining.
The ROS generation was determined by fluorescence
microscopy and flow cytometry following DCFH-DA
staining (Figure 3B). While 1 µM EBR treatment of PANC1 and MIA PaCa-2 cells resulted in no significant increase
in ROS generation, 10 µM EBR treatment induced a
prominent increase in ROS generation. Additionally, these
results have attracted interest to determine the apoptotic
role of EBR in pancreatic cancer cells. Therefore, the
expression role of pro- and antiapoptotic markers was
determined by western blotting (Figure 3C). PANC1 and MIA PaCa-2 cells were treated with 1 and 10 µM
EBR and total protein isolation was performed following
24-h treatment. It was observed that while procaspase 9
expression levels were significantly downregulated, the
cleaved caspase-9 levels showed a remarkable increase
after 10 µM EBR treatment in both MIA PaCa-2 and
PANC-1 cells. Furthermore, 1 µM EBR treatment also
resulted in a slight increase of cleaved caspase 9 in each cell
line. The expression level of procaspase 7 was decreased
in a dose-dependent manner in MIA PaCa-2 and PANC-1
cells (Figure 3C). Both Bax and Puma were proapoptotic
members, while 10 µM EBR treatment increased the Puma
levels in PANC-1 cells, there was an opposite effect in MIA
PaCa-2 cells. However, Bax levels were decreased in EBRtreated PANC-1 and MIA PaCa-2 cells. EBR treatment did
not exert any effect on the antiapoptotic Bcl-2 expression
levels in each cell line.
3.3. EBR induced ER-stress related markers in PANC-1
and MIA PaCa-2 cells
EBR’s role to induce ER stress in pancreatic cancer cells
was further evaluated. The expression levels of BiP,
Calreticulin (CALR): Calnexin (CALNX): PDI, IRE1α,
PERK, and Ero1α were analyzed by western blotting
(Figure 3D). The ER stress is regulated by PERK and
IRE-1α which are transmembrane receptors and their
interaction with BIP makes these receptors inactive.
Firstly, 10 µM EBR treatment increased the PERK levels,
there was no difference in the Ire1a levels in PANC-1 and
MIA PaCa-2 cells. However, 1 µM EBR treatment led
to a significant decrease in IRE1α in PANC-1 cells and
an increase in MIA PaCa-2 cells. Moreover, while 1 µM
EBR did not alter the level of BiP, 10 µM EBR decreased
its expression in both MIA PaCa-2 and PANC-1 cells
(Figure 3D). CALR expression increased after 1 µM EBR
significantly, but not following 10 µM EBR treatment in
MIA PaCa-2 cells. The expression profile of CALR, on the
other hand, increased significantly in a dose-dependent
manner in PANC-1 cells. PDI can act with BiP to control
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Figure 1. EBR treatment reduced the cell viability of pancreatic cancer cells. A. PANC-1 and MIA PaCa-2 cells were treated
with EBR (1, 10, 20, 30 µM) for 24 h B. AsPC-1 cells were treated with 10, 20, 30 µM EBR for 24, 48, and 72 h. Afterward,
the MTT cell viability assay was performed for each pancreatic cancer cell **p < 0.02, ***p < 0.001. C. 5 × 103 cells/well were
seeded into 6 well plates and treated with 1 and 10 µM EBR for 24 h. Subsequently, MIA PaCa-2 D. and PANC-1 cells were
fixed and stained with crystal violet. Trypan blue dye exclusion assay was performed in E. MIA PaCa-2 and F. PANC-1 cells
following 1 and 10 µM EBR treatments for 24, 48, and 72 h.

misfolded protein levels in the cell. Compared to 10 µM
EBR, 1 µM EBR treatment increased the PDI expression

levels in MIA PaCa-2 cells more significantly. Contrarily,
the expression of PDI was downregulated in PANC-1 cells.
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Figure 2. EBR treatment inhibited the cell migration capacity of pancreatic cancer cells. 5 × 105 cells/well were seeded to 6 well plates
and incubated until they reached 80% confluence. Wound Healing assay was performed following 1 and 10 µM EBR treatments of MIA
PaCa-2 (A-B) and PANC-1 (C-D) cells for 24 h. The wound closure was calculated by Olympus IX70 light microscopy *p < 0.05, **p <
0.02, ***p < 0.001.

The Ero1α expression levels were increased following 1
and 10 µM EBR treatments of MIA PaCa-2 and PANC-1
cells (Figure 3D).
3.4. Gemcitabine enhances the antiproliferative effect of
EBR in pancreatic cancer cell lines
To investigate whether EBR could synergistically reduce
cell proliferation with gemcitabine, a higher concentration
of EBR (30 µM) was cotreated with both 10 and 100
µM gemcitabine for 24 h on MIA-PaCa-2, PANC-1,
and AsPC-1 cells (Figures 4A–4C). Ten and 100 µM
gemcitabine reduced cell viability almost by 15% and
20% in MIA PaCa-2 and PANC-1 cells. The ratios of cell
viability of MIA PaCa-2 and PANC-1 cells were 75% and
60% following cotreatments of 30 µM EBR with 10 and
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100 µM gemcitabine, respectively. As AsPC-1 cells are
very aggressive, they were cotreated with 30 µM EBR
and 100 µM gemcitabine for 48 and 72 h. It was observed
that 100 µM gemcitabine treatment caused 30% and 40%
cell viability loss for 48 and 72 h treatments, respectively.
The combination of EBR and gemcitabine led to a further
decrease of cell viability to 50% and 45%, respectively at
48 and 72 h treatments. The cell proliferation capacity
of each pancreatic cancer cell was further inhibited by
the cotreatment of EBR with gemcitabine (Figures 4D
and 4F). The cytotoxic effect of 30 µM EBR and 100 µM
gemcitabine was observed in each cell line in a timedependent manner. The colony formation potential of
AsPC-1 was determined following gemcitabine and EBR
treatment at 48 and 72 h (Figure 4G). Gemcitabine had a
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Figure 3. EBR triggered ER stress-induced apoptosis in a caspase-dependent manner in MIA PaCa-2 and PANC-1 cells. A.
MIA PaCa-2 and PANC-1 cells were treated with 1 and 10 µM EBR for 24 h. Next, PI, DiOC6, DCFH-DA, and DAPI fluorescence
staining proceeded. Stained cells were visualized by Olympus IX70 fluorescence microscopy B. Flow cytometric analysis of DCFHDA staining (5 µM) was performed following EBR treatment of MIA PaCa-2 and PANC-1 cells. C. The expression levels of full
caspase 9, cleaved caspase 9, full caspase 7, Bcl-2, Bax, and PUMA were determined by western blotting following total protein
isolation. D. ER stress-related markers BIP, CALR, CALNX, PDI, IRE1α, PERK, and ERO1α were analyzed by western blotting in
MIA PaCa-2 and PANC-1 cells following 1 and 10 µM EBR treatments. β-actin was used as a loading control.

remarkable effect on the inhibition of colony formation of
AsPC-1 cells. While EBR treatment significantly reduced
the colony numbers, cotreatment of EBR with gemcitabine
further decreased the colony numbers and the diameter of
colonies of AsPC-1 cells.
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3.5. EBR augmented gemcitabine-induced apoptosis in a
caspase-dependent manner in MIA PaCa-2 and PANC-1
cells
PI staining was performed to observe the synergistic effect
of cell death-inducing effect of the combination of EBR
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Figure 4. Cotreatment of EBR and gemcitabine decreased cell viability and inhibited cell proliferation of MIA PaCa-2, PANC-1, and AsPC-1 cells. A. PANC-1 and B.
MIA PaCa-2 cells were treated with 10 and 100 µM gemcitabine with/without 30 µM EBR for 24 h. C. 100 µM gemcitabine and 30 µM EBR was applied both individually and in
combination for 48 and 72 h in AsPC-1 cells. Subsequently, MTT cell viability assay was performed for each cell condition *p < 0.05, **p < 0.02, ***p < 0.001. D. PANC-1, E. MIA
PaCa-2, and F. AsPC-1 cells were treated with indicated EBR and gemcitabine concentration both individually and in combination for 24, 48, 72, and 96 h. Next, a trypan blue assay
was performed to investigate the effect of both gemcitabine and EBR on cell proliferation ***p < 0.001, ****p < 0.0001. G. Colony formation assay was performed in AsPC-1 cells
following EBR and gemcitabine treatment for 48 and 72 h. Colony numbers were calculated for each condition ****p < 0.0001.
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and gemcitabine treatment. The PI-stained (PI-positive
cells) cells were counted (Figure 5A). Here, it was observed
that cotreatment of EBR and gemcitabine resulted in a
more significant increase in the cell death ratio when
compared to alone treatment of gemcitabine and EBR in
each pancreatic cancer cell line. Flow cytometric analysis
following PI staining showed that gemcitabine treatment
induced the cell cycle arrest at the G1 phase by 20% and
there was no significant increase in the subG1 population
in PANC-1 cells (Figure 5B). However, it was observed that
the subG1 levels were 37% in MIA PaCa-2 cells treated
with 100 µM gemcitabine. While 30 µM EBR treatment
did not cause any effect on the cell cycle, the combination
of EBR with gemcitabine increased significantly the
apoptotic cell ratio to 33% and 58% in PANC-1 and MIA
PaCa-2 cells, respectively (Figures 5B and 5C). The G2/M
cell population seen at the 48-h and 72-h incubation of
AsPC-1 cells was almost 37% and 50%, respectively. It was
observed that the ratio of the G2/M population of AsPC-1
cells significantly decreased after 48 and 72 h treatments
of gemcitabine. The combined treatment of EBR with
gemcitabine increased the G1 cell cycle arrest in AsPC-1
cells (Figures 5B–5D). To further investigate the apoptotic
potential of combined treatment, the Bax, Bim, Bak, Bid,
and Bcl-2 levels were determined by immunoblotting
(Figure 5E). The Bak, Bax, and cleaved Bid levels were
increased and antiapoptotic Bcl-2 levels were decreased
in a dose-dependent manner of gemcitabine treatment in
PANC-1 cells. Although cleaved Bid and Bax levels were
increased, it was observed that the Bak and Bim levels were
decreased following 100 µM gemcitabine and 30 µM EBR
treatments in PANC-1 cells. The cotreatment of 100 µM
gemcitabine and 30 µM EBR led to a significant increase
of proapoptotic Bax, Bim, Bak, and Bid expression levels

in MIA PaCa-2 cells. Although EBR alone was determined
to exert a modest apoptotic effect in the PANC-1 and MIA
PaCa-2 cells at 30 µM concentration, when combined with
100 µM gemcitabine, it significantly enhanced apoptosis
via cleavage of caspase-9, caspase-3, and PARP compared
to untreated PANC-1 cells. The cotreatment of EBR
with each concentration of gemcitabine increased the
expression of cleaved caspase-9, caspase-7, and PARP in
MIA PaCa-2 cells (Figure 5F). However, the full version of
the caspase-3 level was higher in treated MIA PaCa-2 cells.
The mesenchymal markers vimentin and N-cadherin were
determined to understand the effect of gemcitabine and
EBR combined treatment on the EMT potential of PANC1 and MIA PaCa-2 cells. The higher expression level of
cleaved PARP was correlated with the downregulation of
both N-cadherin and vimentin expression levels following
gemcitabine and EBR cotreatment in PANC-1 and MIA
PaCa-2 cells. AsPC-1 cells were more resistant to EBR and
gemcitabine treatment. Therefore, EBR and gemcitabine
cotreatment was performed for 48 and 72 h. Afterward, the
apoptotic effect was analyzed (Figure 5G). Gemcitabinealone treatment increased the level of cleaved-PARP more
than only EBR treatment in both 48 h and 72 h. Moreover,
the combined treatment exerted higher cleaved-PARP
levels for 48 h and 72 h in AsPC-1 cells. Bcl-2 levels were
more significantly reduced by the combined treatment
than both alone treatments of EBR and gemcitabine. The
inactive form of Bid levels was decreased by the combined
treatment, whereas there was no significant change in only
EBR or gemcitabine treatment. While Bak levels were
downregulated by cotreatment of EBR in 48 h, a significant
increase was recorded in 72 h cotreatment of EBR and
gemcitabine.
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Figure 5. Cotreatment of EBR and gemcitabine had a potent effect on the induction of apoptosis in each pancreatic cancer cell. A. 100 µM gemcitabine and 30 µM EBR were
applied both individually and in combination to PANC-1 (24 h), MIA PaCa-2 (24 h), and AsPC-1 cells (48 and 72 h). The cells were then stained by PI, and PI-positive cells were
visualized by fluorescence microscopy and counted *p < 0.05, **p < 0.02, ***p < 0.001, ****p < 0.0001. B. At the same drug condition, flow cytometry analysis was performed
following PI staining of PANC-1, MIA PaCa-2, and AsPC-1 cells. Proportions of each phase for C. PANC-1, MIA PaCa-2, D. and AsPC-1 cells are presented here. E. The cells
were treated with 10 and 100 uM gemcitabine with/without 30 µM EBR. The expression levels of Bax, Bim, Bak, Bid, and Bcl-2; F. Caspase 9, caspase 7, caspase 3, Vimentin, and
N-cadherin were analyzed by western blotting in PANC-1 and MIA PaCa-2 cells. β-actin was used as a loading control G. The expression levels of PARP, Bcl-2, Bid, and Bak were
determined by western blotting following 10 and 100 µM gemcitabine with/without 30 µM EBR for 48 and 72 h in AsPC-1. GAPDH was used as a loading control.
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4. Discussion
Pancreatic cancer is one of the deadliest gastrointestinal
malignancies. The prognosis of the disease is poor because
of delayed detection and the limited effectiveness of
therapies. Chemotherapy is the mainstream treatment
against pancreas tumors, especially against unresectable
ones. Although aggressive chemotherapy improves
survival, nearly all patients develop drug resistance.
Gemcitabine, an antimetabolite and deoxycytidine analog
with antineoplastic activity, is used as first-line therapy
alone or in combination. However, side effects such as
myelosuppression and pulmonary toxicity, which occur
in a very rapid way, restrict its usage. On the other hand,
steroid administration is usually recommended to limit
the side effects. EBR is a member of brassinosteroids
(BR) with structural similarity to mammalian steroid
hormones. Besides its critical roles in plant growth and
antioxidant mechanisms, EBR is an apoptotic inducer
in various cancer cells, but not in normal epithelial cells.
EBR was first suggested as a nuclear hormone receptor
(NHR) inhibitor; however, cells without NHR expression
also undergo apoptotic cell death. Our studies indicated
that ER stress induction was one of the main actions of
EBR which was shown by stable isotope labeling by amino
acids in cell culture (SILAC) and mass spectroscopy
analyses (Obakan et al., 2015; Obakan-Yerlikaya et al.,
2017). During ER stress, several signaling pathways are
activated via ER membrane resident receptors PERK,
IRE1α, and ATF6 to improve proper protein folding. If
the stress cannot be handled after folding attempts, then
the receptors can initiate apoptotic cell death. ER stress
response regulation is an important phenomenon in
terms of cancer cell death, survival, or chemoresistance.
Therefore, in this study, we aimed to check the potential
of EBR treatment to elevate gemcitabine response in
pancreatic cancer cells concerning ER stress biomarkers.
Our results indicated that EBR treatment had a significant
effect on the reduction of cell viability of MIA PaCa-2,
PANC-1, and AsPC-1 cells. As AsPC-1 cells had higher
metastatic potential than MIA PaCa-2 and PANC-1, EBR
treatment was carried out for 48 and 72 h. The cell viability
reduction due to the EBR treatment was confirmed for
the first time in the literature for pancreatic cancer cells
with different genetic characteristics. This result was
concluded as an effective approach for the induction of
pancreatic cancer cell apoptosis since the heterogeneity
of pancreatic cancer cells can lead to drug resistance and
poor prognosis [15]. Therefore, in this study, the effect
of EBR was investigated in a dose- and time-dependent
manner in pancreatic cancer cells. Firstly, it was observed
that 10 µM EBR inhibited the colony formation ability
of both PANC-1 and MIA PaCa-2 cells, albeit 1 µM EBR
treatment exerted different results on colony numbers of
PANC-1 and MIA PaCa-2 cells. While 1 µM EBR caused

454

a significant decrease in colony numbers of PANC-1. This
result might be due to the different doubling times of the
cell lines. According to a report by McIntyre and Kim, it
is 28 h for PANC-1, whereas the original doubling time
was reported as 52 h (Deer et al., 2010). Moreover, the cell
proliferation rate of cells was differently affected by EBR
treatment. Although the cell proliferation was inhibited
by EBR treatment, after 48 h, the effect of EBR on the
inhibition of cell proliferation was decreased in both MIA
PaCa-2 and PANC-1 cells. The migration capacity of cells
was prevented by EBR treatment. This result was found to
be correlated with our previous ones which indicate that
EBR can prevent wound healing and migration capacity of
different cell lines (Obakan et al., 2014; Obakan et al., 2014;
Coskun et al., 2015). The decrease in the wound healing
and survival potential of cells indicated that they might
be dead due to apoptotic induction. For this purpose and
according to our previous studies indicating that EBR may
induce apoptotic cell death mechanism in relation with
ROS generation induction, we evaluated the induction of
ROS in pancreatic cancer cells. We found that EBR led to
an increase in ROS generation, which can be prevented by
NAC cotreatment. Mitochondria are considered the main
source of ROS and the increased rate of ROS generation
in cells indicate defective mitochondria with unstable
mitochondrial membrane potential, which usually occurs
following chemotherapeutic agents exposure (Suski et
al., 2012). The loss of mitochondrial membrane potential
eventually causes cell death, mainly apoptosis (Zorov et
al., 2006). The generation of ROS has been also associated
with ER stress in various studies and it has been used as a
therapeutic strategy in cancer models (Cao & Kaufman,
2014). It was recorded that EBR treatment induces ER
stress mainly by targeting calreticulin in prostate cancer
cells (Obakan-Yerlikaya et al., 2017). When pancreatic
cancer was treated with EBR, ER stress is augmented
in a dose-dependent manner and CALR and CALNX
expressions were increased as suggested by our group
in recent studies. EBR treatment-induced apoptotic cell
death was found to be caspase-dependent in pancreatic
cancer cells, supporting previous findings of EBR-induced
cell death mechanism (Modi et al., 2016).
Although the low levels of EBR significantly reduced
cell proliferation, we further investigated a higher dose of
EBR in combination with gemcitabine because at this 30
µM concentration, EBR treatment caused a sharp cytotoxic
effect in each pancreatic cancer cell line treated with
gemcitabine and significantly reduced cell proliferation in
a time-dependent manner. Gemcitabine concentrations
were firstly selected according to the literature; however,
further drug combination optimization clearly showed
that 100 µM and 30 µM EBR concentrations were able to
significantly reduce cell viability and cell proliferation. The
cotreatment of EBR with gemcitabine had a remarkable

OBAKAN YERLİKAYA et al. / Turk J Biol
effect on the inhibition of cell growth of PANC-1 and
MIA PaCa-2 cells. AsPC-1 cells had a more drug-resistant
profile than other pancreatic cancer cells (Awasthi et al.,
2013). Therefore, the colony formation capacity of AsPC1 cells was investigated following gemcitabine and EBR
treatment. Although 100 µM gemcitabine decreased the
colony numbers, EBR cotreatment led to a further decrease
in colony formation capacity of AsPC-1 cells. However,
the EBR and gemcitabine caused the increase of apoptotic
cells in PANC-1 and MIA PaCa-2 cells, while there was no
similar result in AsPC-1 cells. The combined treatment of
new generation drugs with GEM yielded better results in
terms of decrease in the clonogenic potential of pancreatic
cancer cells (Di Matteo et al., 2019; Kwegyir-Afful et al.,
2017). The increased apoptotic induction after cotreatment
with EBR also affected the cell cycle phase distribution
of pancreatic cancer cells. The G1 cell cycle arrest was
observed following EBR and gemcitabine treatment in
AsPC-1 cells. In addition, increased subG1 phase in
all pancreatic cancer cells indicate further apoptotic
induction. Gemcitabine, when combined with several
anti-cancer agents showed the similar effect as EBR in
pancreatic cells, including BH3 mimetic ABT-199, Chk1
inhibitors, or nabpaclitaxel (Bennett et al., 2012; Zhou et
al., 2018; Passacantilli et al., 2018). The further apoptotic
induction with EBR and gemcitabine cotreatment was also
verified with the increase in the cleavages of caspase 9,
caspase 3, and PARP levels in PANC-1 and MIA PaCa-2
cells. Moreover, the proapoptotic Bax and Bak levels were
upregulated, whereas Bcl-2 as an antiapoptotic marker
was downregulated in PANC-1 and MIA PaCa-2 cells. All
these results verified that EBR is a mitochondria-mediated
apoptotic agent that can elevate gemcitabine treatment
in pancreatic cancer cells. Targeting mitochondria
homeostasis has been suggested as an effective strategy to
enhance chemosensitivity (Dubois et al., 2020). Therefore,
it is not surprising that there are recent studies suggesting
that the apoptotic effect of gemcitabine can be augmented
by mitochondria-mediated apoptosis inducers including
oblongifolin C, an autophagy flux inhibitor or doxycycline,
a mitochondrial biogenesis inhibitor (Huang et al., 2020;
Dijk et al., 2020). As investigated in previous studies,

N-cadherin acts as a negative regulator of apoptosis
and it can inhibit PARP cleavage to prevent apoptosis in
various cancer cells (Nguyen et al., 2018). In addition, both
downregulated N-cadherin and vimentin are important
biomarkers of EMT process. While N-cadherin and
vimentin are usually expressed at low level in epithelial
cells, their aberrant expression is a very well-known
phenomenon in breast, prostate, and pancreatic cancer
cells, causing increased aggressiveness and metastasis (Fei
et al., 2015; Mrozik et al., 2018). Our findings suggested
that combined treatment of GEM and EBR decreased their
expression profiles. As N-cadherin and vimentin endow
cancer cells with increased migration and invasiveness,
their further downregulation might suggest the inhibition
of the metastatic potential of the cells.
Currently, the most commonly used treatments that
involve combination partners with gemcitabine are
5-fluorouracil (5-FU): docetaxel, and cisplatin in pancreatic
tumors (Heinemann, 2002). Combinations of gemcitabine
with EBR have important potential to use in the treatment
of pancreatic cancer. Although the combination of
gemcitabine with EBR has demonstrated activity, and
data showing a clear antisurvival benefit, we plan to check
whether gemcitabine-induced chemoresistance can be
achieved by EBR cotreatment and the role of ER stress
during this process.
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